Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Pharma Industry Analysis

UpdatedJun 06, 2026
DataAggregated Company Financials
Companies21
  • 7D2.7%
  • 3M7.7%
  • 1Y-20.3%
  • YTDn/a

The Pharma industry is up 2.7% in the last week, with Camurus up 4.0%. In the same time, Flerie was down 6.4%. In the past year, the industry is down 20%. As for the next few years, earnings are expected to grow by 37% per annum.

Industry Valuation and Performance

Has the Swedish Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 07 Jun 2026SEK 44.6bSEK 5.3b-SEK 1,275,205,144.0068.7x-35x8.5x
Tue, 05 May 2026SEK 44.7bSEK 5.3b-SEK 1,208,469,671.0065.6x-37x8.5x
Thu, 02 Apr 2026SEK 42.4bSEK 5.3b-SEK 1,376,536,671.0056.8x-30.8x8.1x
Sat, 28 Feb 2026SEK 42.5bSEK 5.3b-SEK 1,338,444,873.0056.5x-31.7x8.1x
Mon, 26 Jan 2026SEK 53.4bSEK 5.3b-SEK 1,010,628,157.0069.1x-52.8x10.1x
Wed, 24 Dec 2025SEK 49.1bSEK 5.3b-SEK 531,735,157.0071x-92.3x9.3x
Fri, 21 Nov 2025SEK 49.6bSEK 5.3b-SEK 522,560,865.0069.6x-94.9x9.4x
Sun, 19 Oct 2025SEK 53.3bSEK 5.1b-SEK 405,183,865.0068x-131.5x10.5x
Tue, 16 Sep 2025SEK 55.9bSEK 5.1b-SEK 405,183,865.0077.2x-138x11x
Thu, 14 Aug 2025SEK 52.5bSEK 5.1b-SEK 318,692,364.0071.7x-164.6x10.4x
Sat, 12 Jul 2025SEK 56.4bSEK 4.8b-SEK 525,205,364.0077.4x-107.3x11.8x
Mon, 09 Jun 2025SEK 52.8bSEK 4.8b-SEK 574,396,765.4470.4x-91.9x10.9x
Wed, 07 May 2025SEK 54.0bSEK 4.8b-SEK 940,638,233.7879.3x-57.4x11.3x
Fri, 04 Apr 2025SEK 47.8bSEK 4.7b-SEK 809,145,235.3968.6x-59x10.2x
Sun, 02 Mar 2025SEK 54.7bSEK 4.7b-SEK 763,977,212.7079.6x-71.6x11.7x
Tue, 28 Jan 2025SEK 49.8bSEK 4.4b-SEK 810,061,268.90123.4x-61.4x11.2x
Thu, 26 Dec 2024SEK 50.1bSEK 4.4b-SEK 615,911,477.26125.3x-81.3x11.3x
Sat, 23 Nov 2024SEK 50.3bSEK 4.4b-SEK 620,717,014.43126.6x-81x11.3x
Mon, 21 Oct 2024SEK 53.9bSEK 4.3b-SEK 677,083,649.86136.8x-79.6x12.6x
Wed, 18 Sep 2024SEK 66.5bSEK 5.9b-SEK 1,169,918,052.73174.4x-56.9x11.3x
Fri, 16 Aug 2024SEK 69.0bSEK 5.9b-SEK 946,972,901.7887x-72.9x11.7x
Sun, 14 Jul 2024SEK 69.5bSEK 6.4b-SEK 835,140,932.6385.7x-83.2x10.9x
Tue, 11 Jun 2024SEK 61.9bSEK 6.5b-SEK 918,958,027.6575.2x-67.4x9.6x
Thu, 09 May 2024SEK 51.2bSEK 6.4b-SEK 803,411,939.1268.4x-63.8x8x
Sat, 06 Apr 2024SEK 51.4bSEK 6.2b-SEK 1,038,130,822.6777.9x-49.6x8.2x
Mon, 04 Mar 2024SEK 47.5bSEK 6.2b-SEK 1,038,034,450.5779.1x-45.8x7.6x
Wed, 31 Jan 2024SEK 69.9bSEK 9.5b-SEK 1,181,796,965.0067.1x-59.2x7.4x
Fri, 29 Dec 2023SEK 68.6bSEK 9.4b-SEK 1,184,200,355.0065x-58x7.3x
Sun, 26 Nov 2023SEK 61.2bSEK 9.5b-SEK 1,174,445,030.0054.4x-52.1x6.5x
Tue, 24 Oct 2023SEK 50.4bSEK 9.2b-SEK 1,143,058,911.00104.7x-44.1x5.5x
Thu, 21 Sep 2023SEK 51.2bSEK 9.2b-SEK 1,177,907,877.00134.3x-43.4x5.6x
Sat, 19 Aug 2023SEK 50.6bSEK 9.1b-SEK 1,308,392,355.0082.1x-38.7x5.5x
Mon, 17 Jul 2023SEK 48.2bSEK 8.4b-SEK 1,693,182,186.0081.3x-28.5x5.8x
Wed, 14 Jun 2023SEK 48.2bSEK 8.4b-SEK 1,706,714,871.0077x-28.2x5.8x
Price to Earnings Ratio

-28.2x


Total Market Cap: SEK 48.2bTotal Earnings: -SEK 1,706,714,871.00Total Revenue: SEK 8.4bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Pharma Industry Price to Earnings3Y Average -74.1x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 9.2x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 14% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Comparison

How does Swedish Pharma compare with similar industries?

SE Market-1.09%
Healthcare-0.57%
Pharma2.72%
Pharma2.72%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
CAMX CamurusSEK 547.504.0%
+SEK 1.3b		-14.3%PE48x
DICOT Dicot PharmaSEK 0.2317.7%
+SEK 69.5m		-58.8%PB7.9x
SECARE SwedencareSEK 27.601.1%
+SEK 48.0m		-34.3%PE89.5x
IBT B Infant Bacterial TherapeuticsSEK 57.402.9%
+SEK 21.6m		-1.2%PB9.4x
ENZY EnzymaticaSEK 2.812.9%
+SEK 19.4m		-3.8%PS12.9x

Latest News

SECARE
SEK 27.60
Swedencare
7D
1.1%
1Y
-34.3%
CINPHA
SEK 12.22
Cinclus Pharma Holding
7D
1.8%
1Y
-22.1%
GABA
SEK 0.06
Gabather
7D
59.4%
1Y
22.1%
CAMX
SEK 547.50
Camurus
7D
4.0%
1Y
-14.3%
Narrative Update • Jun 03

CAMX: Expanded Cardiometabolic Partnership Will Support Further Share Price Upside

Analysts have adjusted their price target on Camurus to SEK 914 from SEK 930. This change reflects updated views on growth, profitability, a slightly higher discount rate, and expectations for a lower future P/E multiple.
NEWBRY
SEK 2.03
Newbury Pharmaceuticals
7D
43.0%
1Y
-23.4%
MOB
SEK 9.96
Moberg Pharma
7D
-2.4%
1Y
11.0%
Narrative Update • Jun 02

MOB: Dual Terbinafine Supply And Expanded Licensing Will Support Future Re Rating Potential

Analysts have adjusted their price target on Moberg Pharma to SEK14.00 from SEK13, reflecting updated assumptions around revenue growth, profit margins, discount rate and future P/E. These changes collectively reshape their view of the stock’s risk and reward profile.
DICOT
SEK 0.23
Dicot Pharma
7D
17.7%
1Y
-58.8%
ORX
SEK 18.98
Orexo
7D
-7.4%
1Y
2.6%
Narrative Update • May 30

ORX: Overdose Treatment Progress And Higher Margins Will Support Future Upside

Analysts now see Orexo's fair value at SEK29.0, down from SEK38. This reflects updated assumptions for revenue growth, profit margins and a higher future P/E, alongside a modest increase in the discount rate.
CESSA
DKK 18.25
Cessatech
7D
-3.4%
1Y
24.0%
CLBIO
SEK 18.00
Corline Biomedical
7D
-4.5%
1Y
85.6%
Analysis Article • May 11

We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
KDV B
SEK 0.29
KDventures
7D
-1.7%
1Y
-70.7%
ENZY
SEK 2.81
Enzymatica
7D
2.9%
1Y
-3.8%
IBT B
SEK 57.40
Infant Bacterial Therapeutics
7D
2.9%
1Y
-1.2%
Analysis Article • Apr 20

We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
FLERIE
SEK 21.80
Flerie
7D
-6.4%
1Y
-45.4%
PILA
SEK 1.50
Pila Pharma
7D
-10.7%
1Y
-50.0%
ODI
SEK 2.72
ODI Pharma
7D
-18.6%
1Y
43.2%